Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Analytical Science, Bioprocessing - Upstream & Downstream

“A” Protein of Potential

Protein A is a true workhorse of the pharma industry. It has been used for decades and is well established as the preferred method of purification for monoclonal antibodies because of the high yield and purity achieved in a single step (1). The technique is so common today that it is often referred to by its own acronym: “PAC” – Protein A chromatography (2), but most scientists today take Protein A for granted, without so much of a thought as to where it came from, or how much work the industry has put into refining and enhancing its abilities.

Looking back on the past techniques and technologies in one’s industry is always fascinating. Protein A is naturally occurring and natural selection has bestowed it with high selectivity. It was first discovered in 1958 when Klaus Jensen at the University of Copenhagen reported the existence of an antigen associated with staphylococci that reacted with 500 types of normal human serum. He called this antigen “Antigen A”. Four years later, two professors from the University of Umeå (Sweden), John Sjöquist and Torvald Löfkvist, demonstrated that the so-called antigen was actually a surface-wall protein on the Staphylococcus aureus bacteria. Two years thereafter, the Bergen group gave the protein its current name, Protein A. However, it was not until 1966 that Sjöquist and a doctoral fellow, Arne Forsgren, published the results of crucial experiments demonstrating that Protein A bound to the Fc part of IgG. The interaction was described as a pseudo-immune reaction and sparked a great deal of additional research on the microbiology, biochemistry and biological activity of the protein (3).

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Jonathan Royce

Jonathan Royce is BioProcess Senior Product Manager of Antibody Affinity Resins at GE Healthcare.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register